How Guardant Is Redefining Cancer Detection

Guardant Health’s co-founder and CEO, Helmy Eltoukhy reveals how the company has been making huge waves in the field of liquid biopsy.

Omar Ford

September 9, 2022

1 Min Read

For the past 10 years, Guardant Health has been defining the liquid biopsy space and has been a pioneer of sorts in the cancer detection market. The private company was one of the first in the space to go public and has secured a few FDA approvals to boot.

Guardant’s CEO and Co-founder Helmy Eltoukhy joins us for this episode of Let’s Talk Medtech to discuss the company’s past, present, and future. We also discuss the evolution of liquid biopsy and why the method holds so much promise for cancer detection.

About the Author(s)

Omar Ford

Omar Ford is MD+DI's Editor-in-Chief. You can reach him at [email protected].


Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like